A phase II study of the 5-lipoxygenase inhibitor, CV6504, in advanced pancreatic cancer: correlation of clinical data with pharmacokinetic and pharmacodynamic endpoints. [electronic resource]
Producer: 20010215Description: 1165-70 p. digitalISSN:- 0923-7534
- Antineoplastic Agents -- pharmacokinetics
- Benzoquinones -- pharmacokinetics
- Disease Progression
- Disease-Free Survival
- Drug Evaluation
- Female
- Humans
- Linoleic Acid -- blood
- Lipoxygenase Inhibitors -- pharmacokinetics
- Male
- Middle Aged
- Pancreatic Neoplasms -- drug therapy
- Thromboxane B2 -- antagonists & inhibitors
No physical items for this record
Publication Type: Clinical Trial; Clinical Trial, Phase II; Controlled Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.